Sequential use of second‐generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group

摘要

Abstract Background The details of the sequential use of imatinib for first‐line treatment followed by second‐generation tyrosine kinase inhibitors (2G‐TKIs) for pediatric chronic myeloid leukemia (CML) are still unknown. This study analyzed clinical responses and adverse effects of the use of 2G‐TKIs following imatinib in pediatric chronic phase (CP)‐CML. Procedures The Japanese Pediatric Leukemia/Lymphoma Study Group conducted a retrospective study of patients with newly diagnosed CML from 1996 to 2011. A total of 152 cases that received imatinib as first‐line therapy were analyzed. Results Excluding 46 cases treated with hematopoietic stem cell transplantation before nilotinib and dasatinib became available, 31 of 106 patients changed to 2G‐TKIs. The primary reason for changing from imatinib was poor response, followed by intolerance, with the main reason for the latter being musculoskeletal events. Switches from imatinib to 2G‐TKIs with intolerance occurred significantly earlier than switches with poor response. Sixteen and 15 patients were treated with nilotinib and dasatinib, respectively, following imatinib therapy. After switching to 2G‐TKIs, the response status improved in 63% of evaluable patients. The adverse effect profiles of nilotinib and dasatinib tended to be different, with hyperbilirubinemia observed in 33% of nilotinib‐treated patients, but in none of the cases with dasatinib. Conclusion This retrospective study represents the first series of children and adolescents in whom sequential use of imatinib followed by 2G‐TKIs was reported. These data provide useful insights into the selection of 2G‐TKIs as first‐line treatment for children and adolescents with CP‐CML.